<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The effect of KW-2228, a derivative of recombinant human granulocyte colony stimulating factor, on <z:hpo ids='HP_0001875'>neutropenia</z:hpo> in children was studied in 23 cases of <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo>, 13 cases of <z:hpo ids='HP_0011010'>chronic</z:hpo> benign <z:hpo ids='HP_0001875'>neutropenia</z:hpo>, 6 cases of <z:hpo ids='HP_0005549'>congenital neutropenia</z:hpo> (<z:e sem="disease" ids="C0340970" disease_type="Disease or Syndrome" abbrv="">Kostmann</z:e> type), 2 cases of cyclic <z:hpo ids='HP_0001875'>neutropenia</z:hpo>, 2 cases associated with <z:e sem="disease" ids="C0017919" disease_type="Disease or Syndrome" abbrv="">glycogenosis</z:e> type Ib and 1 cases associated with <z:hpo ids='HP_0002721'>immune deficiency</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>KW-2228 was administered at 1-8 micrograms/kg subcutaneously and at 2-16 micrograms/kg intravenously </plain></SENT>
<SENT sid="2" pm="."><plain>As a principle, the administration was started at low doses and continued for 7-28 days increasing the doses in the cases who didn't respond to the treatment well </plain></SENT>
<SENT sid="3" pm="."><plain>The response rate of <z:hpo ids='HP_0000001'>all</z:hpo> the cases by the physicians in charge was 81 </plain></SENT>
<SENT sid="4" pm="."><plain>8% (36/44) </plain></SENT>
<SENT sid="5" pm="."><plain>The mean absolute neutrophil count was increased from 304 to 1,300/microliters in <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo>, from 204 to 3,027/microliters in <z:hpo ids='HP_0011010'>chronic</z:hpo> benign type, from 125 to 2,193/microliters in <z:e sem="disease" ids="C0340970" disease_type="Disease or Syndrome" abbrv="">Kostmann</z:e> type, and from 360 to 2,007 microliters in others </plain></SENT>
<SENT sid="6" pm="."><plain>KW-2228 did not induce any noteworthy serious side effects </plain></SENT>
<SENT sid="7" pm="."><plain>These results indicated that KW-2228 is a useful drug to treat <z:hpo ids='HP_0001875'>neutropenia</z:hpo> in children </plain></SENT>
</text></document>